Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757644 | 1.00 | ACLY (0.51) | ACLYHTR6SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL2930564 | 1.00 | ACLY (0.51) | ACLYHTR6SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL2929510 | 0.88 | GAA (0.45) | ACLYHTR6SMN1; SMN2ALDH1A1PTGDR2 | |
| SCHEMBL2927961 | 0.88 | GAA (0.45) | ACLYHTR6SMN1; SMN2ALDH1A1PTGDR2 | |
| SCHEMBL2927960 | 0.88 | GAA (0.45) | ACLYHTR6SMN1; SMN2ALDH1A1PTGDR2 | |
| SCHEMBL4759367 | 0.83 | ACLY (0.53) | ACLYHTR6SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL4757349 | 0.81 | CXCR2 (0.45) | ACLYSMN1; SMN2ALDH1A1TP53L3MBTL1 | |
| SCHEMBL5823347 | 0.80 | ACLY (0.62) | ACLYHTR6PPARGPPARAPPARD | |
| SCHEMBL4757347 | 0.79 | TDP1 (0.42) | SMN1; SMN2ALDH1A1TP53L3MBTL1PTGDR2 | |
| SCHEMBL2928718 | 0.77 | ACLY (0.55) | ACLYPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | ACLY 3558/4885HTR6 536/4885SMN1; SMN2 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.